Indeed, SRM has been used to characterize amyloid-beta (Aβ) and tau aggregates in CSF samples of AD patients and allowed for distinguishing AD patients from HC subjects (Zhang et al., 2015). This evidence concerns the gene MAPT and Alzheimer disease.